Navigation Links
Micell Technologies' Rapid Absorption Polymer DES System to be Presented at CRT 2009

RALEIGH, N.C., March 4 /PRNewswire/ -- Micell Technologies announced today that David E. Kandzari, MD, will present "The Micell Rapid Absorption Polymer DES System" during the Cardiovascular Research Technologies (CRT) meeting in Washington, DC, on March 5, 2009. MiStent(TM), a Drug-Eluting Stent (DES) in pre-clinical studies, utilizes a bioasorbable polymer coating that delivers the potential benefits of the drug during the healing process. The proprietary formulation allows the polymer to be absorbed concurrent with the drug delivery rather than sequentially like other absorbable DES coatings. This allows both the polymer and drug to be eliminated within 90 days and provides the potential for improved patient benefits.

"The Micell DES technology is exciting because it is the first of a new generation of stents being developed to precisely deliver a drug while safely eliminating the polymer faster than any other bioabsorbable coating that is commercially available," said Kandzari. "The unique formulation that allows the polymer to be absorbed at the same time that the drug is being delivered offers the therapeutic benefits of a drug-eluting stent, while quickly transforming itself to the safety profile of a bare metal stent."

Earlier this year, Micell obtained the rights to a CE marked cobalt chromium stent to use as its platform for its proprietary coating. Arthur J. Benvenuto, Chairman and Chief Executive Officer of Micell, said, "The pieces are quickly coming together as we demonstrate the advantages of our proprietary formulation and deliver it on a state-of-the-art stent with the lowest strut thickness commercially available. Our scalable drug and polymer coating process serves as a platform for the development of innovative interventional cardiology systems."

Dr. Kandzari is the Director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, CA.

About Micell Technologies Inc.

Micell Technologies is a privately-held, development-stage biomedical device company dedicated to developing innovative interventional cardiology systems. By applying its unique surface and polymer modification technologies, Micell can precisely and consistently control drug elution and the duration of polymer exposure creating the potential for a therapeutic solution for coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Its first product in development, MiStent(TM), is a rapid absorbing coated drug-eluting stent with precise control of drug release and pharmacokinetics. Visit us at

    Contact: Micell Technologies

    Arthur J. Benvenuto, Chairman & CEO
    (919) 313-2104

SOURCE Micell Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Micell Rapid Absorption Polymer DES System to be Presented at TCT 2008
2. Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
7. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
8. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
9. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
10. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
(Date:6/23/2016)... 2016 adds 2016 ... its pharmaceuticals section with historic and forecast data ... more. Complete report on the Cell ... 15 companies and supported with 261 tables and ... . The Global Cell Culture Media ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
Breaking Biology News(10 mins):